RM-MET / Metabolic and incretin signalling
Petrelintide
Also known as: ZP8396
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Petrelintide is the current nonproprietary name for ZP8396, an investigational long-acting amylin analog.
Evidence position
Published randomized phase 1 studies support Grade C. This is stronger than a preclinical-only record but not equivalent to a large confirmatory trial program.
What the record does not establish
The literature does not authenticate an outside vial or prove its exact modification, concentration, sterility or stability.
Sources
- 01Petrelintide compound recordPubChem
- Shows
- Registry identity, structure, formula and molecular properties
- Does not show
- Chemical identity does not establish clinical status or lot quality
- 02Petrelintide randomized phase 1 trialsPubMed
- Shows
- Published human safety, pharmacokinetic and exploratory weight data
- Does not show
- Early-phase sponsor-funded evidence; confirmatory trials remain necessary
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Petrelintide
- CID
- 172915807
- Formula
- C185H305N49O61
- Mass
- 4192
PUBMED / FOUND RECORDS
- Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.Journal of medicinal chemistry / 2025 Jul 24PMID 40608546 / DOI 10.1021/acs.jmedchem.5c01120
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.Vascular pharmacology / 2026 MarPMID 41344603 / DOI 10.1016/j.vph.2025.107563
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.Peptides / 2026 MarPMID 41747885 / DOI 10.1016/j.peptides.2026.171480
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.Journal of medicinal chemistry / 2025 Nov 27PMID 41217931 / DOI 10.1021/acs.jmedchem.5c01185
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.Diabetes, obesity & metabolism / 2026 JulPMID 42017294 / DOI 10.1111/dom.70753
CLINICALTRIALS.GOV / FOUND RECORDS
- Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic FunctionRECRUITING / PHASE1 / Zealand PharmaNCT07682818 / DIRECT intervention MATCH: Petrelintide
- Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsCOMPLETED / PHASE1 / Zealand PharmaNCT07338214 / DIRECT intervention MATCH: Petrelintide
- A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNOT_YET_RECRUITING / PHASE2 / Hoffmann-La RocheNCT07589686 / DIRECT intervention MATCH: Petrelintide
- Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal FunctionCOMPLETED / PHASE1 / Zealand PharmaNCT07076030 / DIRECT intervention MATCH: Petrelintide
- Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)ACTIVE_NOT_RECRUITING / PHASE2 / Zealand PharmaNCT06926842 / DIRECT intervention MATCH: Petrelintide